One thing is obvious. For the health or social care system there’s no going back to the status quo of February 2020 before the unprecedented disruption of Covid-19.
Healthcare bodies have adapted. In May 2020 the NHS Operating Model Framework called for a “focus on clinically-led pathway improvements to limit unnecessary hospital attendance and reduce risks for patients requiring hospital treatments.” The King’s Fund has highlighted that innovations are emerging locally and less visibly, making it harder to measure impact.
In many ways, the current crisis has accelerated developments already underway, which have implications for both healthcare providers and pharmaceutical and biotech companies.
In an exclusive conversation with Pharmafield Magazine, we explore those implications and share 6 future-focused capabilities that we’ve identified as essential for pharmaceutical and biotech companies to develop so their key accounts thrive.
To build on what we shared with Pharmafield Magazine, we’ve developed this guide:
‘Crisis or crossroads where next for key account management? Insights on what is needed now for key accounts to flourish post COVID’
To access your copy of the guide, just complete the form below.